Suggested citation: Effective Practice and Organisation of Care (EPOC). Data collection form. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services; 2013. Available at: <a href="http://epoc.cochrane.org/epoc-specific-resources-review-authors">http://epoc.cochrane.org/epoc-specific-resources-review-authors</a>



# Data collection form

#### Intervention review – RCTs and non-RCTs

This form can be used as a guide for developing your own data extraction form. Sections can be expanded and added, and irrelevant sections can be removed. It is difficult to design a single form that meets the needs of all reviews, so it is important to consider carefully the information you need to collect, and design your form accordingly. Information included on this form should be comprehensive, and may be used in the text of your review, 'Characteristics of included studies' table, risk of bias assessment, and statistical analysis.

#### Notes on using a data extraction form:

**Review title or ID** 

- Be consistent in the order and style you use to describe the information for each included study.
- Record any missing information as unclear or not described, to make it clear that the information was not found in the study report(s), not that you forgot to extract it.
- Include any instructions and decision rules on the data collection form, or in an accompanying document. It is important to practice using the form and give training to any other authors using the form.
- You will need to protect the document in order to use the form fields (Tools / Protect document)

Study ID (surname of first author and	d year first full report of study was published e.g. Smith 2001)
Report IDs of other reports of this st	tudy (e.g. duplicate publications, follow-up studies)
Notes:	
Notes.	
1 General Information	
Date form completed	
(dd/mm/yyyy)	
2. Name/ID of person extracting	
data	
3. Report title	
(title of paper/ abstract/ report	
that data are extracted from)	
4. Report ID	
(if there are multiple reports of this	
study) 5. Reference details	
5. Keterence details	
6. Report author contact details	

(e.g. full report, abstract, letter)

7. Publication type

8. Study funding source (including role of funders)
Possible conflicts of interest
(for study authors)
9. Notes:

# 2... Eligibility

Study	Review Inclusion Criteria		Location in text
Characteristics	(Insert inclusion criteria for each characteristic as		(pg & ¶/fig/table)
	defined in the Protocol)	Yes/ No / Unclear	
10. Type of study	Randomised trial		
		•	
	Non-randomised trial	·	
	Controlled before-after study		
	<ul> <li>Contemporaneous data collection</li> <li>At least 2 intervention and 2 control clusters</li> </ul>		
	Interrupted time series OR	·	
	Repeated measures study  • At least 3 timepoints before and		
	3 after the intervention		
	Clearly defined intervention point		
	Other design (specify):		
11. Participants			
12. Types of intervention		•	
13. Types of outcome			
measures		•	
14. Decision:			
15. Reason for exclusion			
16. Notes:			

DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW

## 3... Population and setting

	Description	Location in text
	Include comparative information for each group (i.e. intervention and controls) if available	(pg & ¶/fig/table)
17. Population		
description		
(from which study		
participants are drawn)		
18. Setting		
(including location and		
social context)		
19. Inclusion criteria		
20. Exclusion criteria		
21. Method/s of		
recruitment of		
participants		
22. Notes:		

### 4... Methods

	Descriptions as stated in report/paper	Location in text
		(pg & ¶/fig/table)
23. Aim of study		
24. Design		
(e.g. parallel, crossover,		
non-RCT)		
25. Unit of allocation		
(by individuals, cluster/		
groups or body parts)		
26. Start date		
27. End date		
28. Duration of		
participation		
(from recruitment to last		
follow-up)		
29. Notes:		·

#### 5... Risk of Bias assessment

See <u>Chapter 8</u> of the Cochrane Handbook. Additional domains may be required for non-randomised studies.

see chapter of the coemane handbook. Additional domains may be required for non randomised stadies.					
Domain	Risk of bias	Support for judgement	Location in text		
	Low/ High/Unclear		(pg & ¶/fig/table)		
30. Random sequence generation					
(selection bias)	•				
31. Allocation concealment					
(selection bias)	•				

Domain	Risk of bias Low/ High/Unclear	Support for judgement	Location in text (pg & ¶/fig/table)
32. Blinding of participants and personnel (performance bias)		Outcome group: All/	, ,
(if required)		Outcome group:	
33. Blinding of outcome assessment (detection bias)		Outcome group: All/	
(if required)	•	Outcome group:	
34. Incomplete outcome data (attrition bias)	•		
35. Selective outcome reporting? (reporting bias)	•		
36. Other bias	•		
37. <b>Notes:</b>		•	

## **6...** Participants

Provide overall data and, if available, comparative data for each intervention or comparison group.

	Description as stated in report/paper	Location in text
		(pg & ¶/fig/table)
38. Total no. randomised		
(or total pop. at start of study		
for NRCTs)		
39. Clusters		
(if applicable, no., type, no.		
people per cluster)		
40. Baseline imbalances		
41. Withdrawals and		
exclusions		
(if not provided below by		
outcome)		
42. <b>Age</b>		
43. <b>Sex</b>		
44. Race/Ethnicity		
45. Severity of illness		
46. Co-morbidities		
47. Other treatment received		
(additional to study		
intervention)		
48. Other relevant		
sociodemographics		
49. Subgroups measured		
50. Subgroups reported		
51. Notes:		

## **7...** Intervention groups

Copy and paste table for each intervention and comparison group

### **Intervention Group 1**

	Description as stated in report/paper	Location in text
52. <b>Group name</b>		(pg & ¶/fig/table)
53. No. randomised to group		
(specify whether no. people		
or clusters)		
54. Description		
(include sufficient detail for		
replication, e.g. content,		
dose, components; if it is a		
natural experiment, describe		
the pre-intervention)		
55. Duration of treatment		
period		
56. <b>Timing</b>		
(e.g. frequency, duration of		
each episode)		
57. <b>Delivery</b>		
(e.g. mechanism, medium,		
intensity, fidelity)		
58. <b>Providers</b>		
(e.g. no., profession, training,		
ethnicity etc. if relevant)		
59. <b>Co-interventions</b>		
60. Economic variables		
(i.e. intervention cost,		
changes in other costs as		
result of intervention)		
61. Resource requirements to		
replicate intervention		
(e.g. staff numbers, cold		
chain, equipment)		
62. Notes:		

### 8... Outcomes

Copy and paste table for each outcome.

#### Outcome 1

	Description as stated in report/paper	Location in text
		(pg & ¶/fig/table)
63. Outcome name		
64. Time points measured		
(specify whether from start		
or end of intervention)		
65. Time points reported		

	Description as stated i	n report/paper	Location in text
66. Outcome definition			(pg & ¶/fig/table)
(with diagnostic criteria if			
relevant and note whether			
the outcome is desirable or			
undesirable if this is not			
obvious)			
67. Person measuring/			
reporting			
68. Unit of measurement			
(if relevant)			
69. Scales: upper and lower			
limits			
(indicate whether high or			
low score is good)			
70. Is outcome/tool			
validated?	Yes/No/Unclear		
71. Imputation of missing			
data			
(e.g. assumptions made for			
ITT analysis)			
72. Assumed risk estimate			
(e.g. baseline or population			
risk noted in Background)			
73. <b>Notes:</b>			

### 9... Results

Copy and paste the appropriate table for each outcome, including additional tables for each time point and subgroup as required.

#### For randomised or non-randomised trial - Dichotomous outcome

	Description as stated in report/paper				Location in text (pg & ¶/fig/table)
74. Comparison					
75. Outcome					
76. Subgroup					
77. <b>Time point</b> (specify whether from start or end of intervention)					
78. Results	Intervention	1	Comparison	1	
Note whether:     post-intervention OR     change from baseline And whether     Adjusted OR     Unadjusted	No. events	No. participants	No. events	No. participants	
79. Baseline data	Intervention	1	Comparison	<u> </u>	
	No. events	No. participants	No. events	No. participants	
80. No. missing participants and reasons		1		1	

	Description as stated in report/paper	Location in text (pg & ¶/fig/table)
81. No. participants moved from other group and		
reasons 82. Any other results reported		
83. Unit of analysis (e.g. by individuals, health professional, practice, hospital, community)		
84. Statistical methods used and appropriateness of these methods (e.g. adjustment for correlation)		
85. Reanalysis required? (if yes, specify why, e.g. correlation adjustment)	Yes/No/Unclear	
86. Reanalysis possible?	Yes/No/Unclear	
87. Reanalysed results 88. Notes:		

#### For randomised or non-randomised trial - Continuous outcome

							Location in text (pg & ¶/fig/table)
89. Comparison							(pg a 11/1:g/ ca.z.c/
90. Outcome							
91. Subgroup							
92. Time point							
(specify whether fro	om						
start or end of							
intervention)							
93. Post-interventi	on or						
change from							
baseline?							
94. Results	Interv	ention		Compa	rison		
Note whether:	Mean	SD (or other	No.	Mean	SD (or other	No.	
• post-		variance)	participants		variance)	participants	
intervention OR							
<ul> <li>change from.</li> </ul>							
baseline							
And whether							
<ul> <li>Adjusted OR.</li> </ul>							
<ul> <li>Unadjusted</li> </ul>							
95. Baseline data	Interv	ention		Compa	rison		
	Mean	SD (or other	No.	Mean	SD (or other	No.	
		variance)	participants		variance)	participants	
96. No. missing		•		•	•	•	
participants and							
reasons							

	Description as stated in report/paper	Location in text
		(pg & ¶/fig/table)
97. No. participants		
moved from other		
group and reasons		
98. Any other results		
reported		
99. Unit of analysis		
(e.g. by individuals,		
health professional,		
practice, hospital,		
community)		
100. Statistical		
methods used and		
appropriateness of		
these methods		
(e.g. adjustment for		
correlation)		
101. Reanalysis		
required?	Yes/No/Unclear	
(if yes, specify why)		
102. Reanalysis		
possible?	Yes/No/Unclear	
103. Reanalysed		
results		
104. Notes:		

#### For randomised or non-randomised trial - Other outcome

		Description as st	ated in report/pa	aper		Location in text (pg & ¶/fig/table)
105.	Comparison					
106.	Outcome					
107.	Subgroup					
108.	Time point					
(spec	ify whether from					
start	or end of					
inter	vention)					
109.	Type of outcome					
110.	Results	Intervention	SD (or other	Control result	SD (or other	
		result	variance)		variance)	
					,	
		Overall results	Į.	SE (or other var	riance)	
				SE (OF OTHER VAI	lance	
111.	No. participant	Intervention		Control		
112.	No. missing					1
p	articipants and					
re	easons					
113.	No. participants					
m	noved from other					
gı	roup and reasons					
114.	Any other results					
re	eported					

	Description as stated in report/paper	Location in text
		(pg & ¶/fig/table)
115. Unit of analysis		
(e.g. by individuals, health		
professional, practice,		
hospital, community)		
116. Statistical methods		
used and		
appropriateness of		
these methods		
117. Reanalysis		
required?		
(if yes, specify why)		
118. Reanalysis		
possible?		
119. Reanalysed results		
120. <b>Notes:</b>		

For controlled before-after study

For co	ontrollea before-after	stuay				
		Description as st	ated in report/p	aper		Location in text (pg & ¶/fig/table)
121.	Comparison					
122.	Outcome					
123.	Subgroup					
124.	Timepoint					
	fy whether from					
	or end of					
interv	rention)					
125.	Post-intervention					
	change from					
ba	seline?		1	1	<b>,</b>	
126.	Results	Intervention	SD (or other	Control result	SD (or other	
		result	variance)		variance)	
		Overall results		SE (or other varia	nce)	
				- (0. 0		
127.	No. participants	Intervention		Control		
						1
128.	No. missing					
pa	irticipants and					
re	asons					
129.	No. participants					
	oved from other					
gr	oup and reasons					
130.	Any other results					
re	ported					
131.	Unit of analysis					
-	iduals, cluster/					
group	s or body parts)					
132.	Statistical					
	ethods used and					
	propriateness of					
th	ese methods					

	Description as stated in report/paper	Location in text (pg & ¶/fig/table)
133. Reanalysis required? (specify)	. Yes/No/Unclear	
134. Reanalysis possible?	. Yes/No/Unclear	
135. Reanalysed results 136. Notes:		

## For interrupted time series or repeated measures study

		Description as stated in report/paper				Location in text	
427	Commonicon						(pg & ¶/fig/table)
137.	Comparison						
138.	Outcome						
139.	Subgroup						
140.	Length of timepoints						
	easured						
	days, months)						
	period measured						
141.	No. participants						
m	easured						
142.	No. missing						
pa	articipants and reasons			T			
143.	No. timepoints	144. Pre-interver	ntion	145.	Post-interv	ention	
m	easured						
146.	Mean value						
(with	variance measure)						
147.	Difference in means						
(p	ost – pre)						
148.	Percent relative						
ch	nange						
149.	Result reported by						
aı	uthors						
(with	variance measure)						
150.	Unit of analysis						
(indiv	riduals or cluster/						
group							
151.	Statistical methods						
	sed and						
-	propriateness of these						
	ethods						
152.	Reanalysis required?						
(spec		Yes/No/Unclear					
153.	Reanalysis possible?	Vas/Na/Unalags					
154	Individual times as aimt	Yes/No/Unclear					
154.	Individual timepoint						
155.	Read from figure?						
133.	neau iroin ligure:	Yes/No/Unclear					
156.	Reanalysed results	Change in level	SE	Chang	e in slope	SE	
	•	Change in level	J.	Chang	c iii siope	J.	-
455	N-4			<u> </u>			
157.	Notes:						

# 10. Applicability

158. Have important	
populations been	Yes/No/Unclear
excluded from the study?	
(consider disadvantaged	
populations, and possible	
differences in the	
intervention effect)	
159. Is the intervention	
likely to be aimed at	Yes/No/Unclear
disadvantaged groups?	
(e.g. lower socioeconomic	
groups)	
160. Does the study	
directly address the	Yes/No/Unclear
review question?	
(any issues of partial or	
indirect applicability)	
161. <b>Notes:</b>	

## 11. Other information

	Description as stated in report/paper	Location in text (pg & ¶/fig/table)
162. Key conclusions of study authors		
163. References to other relevant studies		
164. Correspondence required for further study information (what and from whom)		
165. Further study information requested (from whom, what and when)		
166. Correspondence received (from whom, what and when)		
167. <b>Notes:</b>	•	